Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tata Stl 426.60 1.32
Hindalco 144.70 0.00
Bhel 189.30 1.42
Larsen & 1377.30 2.48
Wipro Lt 525.00 1.19
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Aurobindo Pharma Limited
Aurobindo Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524804NSE:AUROPHARMABloomberg:ARBP@INReuters:ARBN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE406A01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
01-APR-14 Aurobindo Pharma announced the completion of the previously announced acquisition of certain commercial operations in Western Europe from Actavis. The agreement to acquire the Actavis operations was announced in January 2014. 23-JAN-14 Aurobindo Pharma, a mid-size pharmaceutical company, today announce that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Repaglinid...   More..
Business Profile Future Plans
CEO Talk
Aurobindo Pharma, plans to complete restructuring and expansion programme during Q4 FY 2001-02. The company plans to achieve a turnover of above Rs 4,000 crore by FY 2005-06 with formulations accounting for 30 per cent. Joint ventures in US and China are expected boost the company`s international revenues.  Srinivas Lanka
One To One
Recent news
Latest News
Aurobindo completes acquisition of select Western European biz of Actavis  -IRIS 01-Apr-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2013 (12)31-Mar-2012 (12)31-Mar-2011 (12)
Net sales 53529.1042046.1041331.20
Other Income150.10190.6079.90
Total Income53679.2042236.7041411.10
Cost of goods sold44670.4036864.6031314.20
OPBDIT9008.805372.1010096.90
PAT4959.90-426.105938.00
Gross Block---
Equity capital291.20291.10291.10
EPS (Rs.)17.04-1.4620.63
DPS (Rs.)---
BV (Rs.)---
P/E range (x)5.85 - 12.02NA7.59 - 66.65
Debt / Equity (x)---
Operating margin (% of OI)16.812.724.4
Net margin (% of OI) 9.2-1.014.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Plot No 2
Maitri Vihar
Ameerpet
Hyderabad
Andhra Pradesh-500 038
PHONE
(040) 6672 5000
FAX
(040) 2374 1080/ 6833
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer